approval
saveRINVOQ (UPADACITINIB) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025 · 360d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalAug 12, 2025 · 419d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 28, 2025 · 525d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMar 26, 2025 · 558d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 892d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 892d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalNov 14, 2023 · 1056d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalJun 22, 2023 · 1201d ago
same company · ±60 days · 6
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 23, 2022
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 23, 2022
- approvalprednisolone acetate: PRED MILD (PREDNISOLONE ACETATE) — FDA approvalDec 8, 2022
- approvalprednisolone acetate: PRED MILD (PREDNISOLONE ACETATE) — FDA approvalDec 8, 2022
- approvalCARIPRAZINE HYDROCHLORIDE: VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalDec 16, 2022
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalAug 24, 2022
comments(0)
5-min edit window · permanent after that